ArticleBMC ophthalmology2026
Evaluation of visual outcomes, optical quality, and patient satisfaction with a novel monofocal intraocular lens.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the visual outcomes, refractive accuracy, contrast sensitivity, and safety profile of the ENOVA GF3 hydrophobic monofocal intraocular lens following cataract surgery. MATERIALS AND
methodsThis retrospective study included 153 eyes of 105 patients who underwent uneventful phacoemulsification with implantation of the ENOVA GF3 intraocular lens. Postoperative examinations were performed at 0–3 days, 7–10 days, 1–2 months, 4–6 months, and 11–12 months. Uncorrected and corrected distance visual acuity (UCVA and CDVA), refractive outcomes, and contrast sensitivity under photopic and mesopic conditions were evaluated. Statistical analyses were performed using the Wilcoxon signed-rank test, and a p value < 0.05 was considered statistically significant.
resultsA significant improvement was observed in both UCVA and CDVA at all postoperative time points compared with preoperative values (p < 0.001). At the 12-month follow-up, mean UCVA and CDVA reached 0.03 ± 0.06 logMAR and 0.00 ± 0.02 logMAR, respectively. The mean spherical equivalent improved significantly from preoperative values to 0.33 ± 0.21 D at 11–12 months postoperatively (p < 0.001), indicating high refractive accuracy and stability. Contrast sensitivity measurements demonstrated a significant improvement over time under both photopic and mesopic conditions. At 11–12 months, contrast sensitivity values were significantly higher than those measured at 1–2 months across all spatial frequencies (p < 0.05). No intraoperative complications or clinically significant postoperative adverse events, including clinically significant posterior capsular opacification requiring Nd: YAG capsulotomy, were observed during the follow-up period.
conclusionThe ENOVA GF3 monofocal intraocular lens demonstrated excellent visual and refractive outcomes with stable long-term performance. Significant improvements in visual acuity and contrast sensitivity were observed throughout follow-up, with high refractive predictability and no clinically relevant safety concerns. These findings support the ENOVA GF3 as a reliable option for routine cataract surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.